🇺🇸 FDA
Patent

US 8697836

Composition and method for inducing and enhancing a telomerase reverse transcriptase-reactive cytotoxic T lymphocyte response

granted A61KA61K2239/49A61K2239/50

Quick answer

US patent 8697836 (Composition and method for inducing and enhancing a telomerase reverse transcriptase-reactive cytotoxic T lymphocyte response) held by The Regents of the University of California expires Mon Apr 10 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Apr 15 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 10 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
12
CPC classes
A61K, A61K2239/49, A61K2239/50, A61K2239/55, A61K2239/57